» Articles » PMID: 19589785

HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2009 Jul 11
PMID 19589785
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

A group of breast cancer patients with a higher probability of developing metastasis expresses a series of carboxyl-terminal fragments (CTFs) of the tyrosine kinase receptor HER2. One of these fragments, 611-CTF, is a hyperactive form of HER2 that constitutively establishes homodimers maintained by disulfide bonds, making it an excellent model to study overactivation of HER2 during tumor progression and metastasis. Here we show that expression of 611-CTF increases cell motility in a variety of assays. Since cell motility is frequently regulated by phosphorylation/dephosphorylation, we looked for phosphoproteins mediating the effect of 611-CTF using two alternative proteomic approaches, stable isotope labeling with amino acids in cell culture and difference gel electrophoresis, and found that the latter is particularly well suited to detect changes in multiphosphorylated proteins. The difference gel electrophoresis screening identified cortactin, a cytoskeleton-binding protein involved in the regulation of cell migration, as a phosphoprotein probably regulated by 611-CTF. This result was validated by characterizing cortactin in cells expressing this HER2 fragment. Finally, we showed that the knockdown of cortactin impairs 611-CTF-induced cell migration. These results suggest that cortactin is a target of 611-CTF involved in the regulation of cell migration and, thus, in the metastatic behavior of breast tumors expressing this CTF.

Citing Articles

Requirement of Site-Specific Tyrosine Phosphorylation of Cortactin in Retinal Neovascularization and Vascular Leakage.

Kumar R, Rottner K, Rao G Arterioscler Thromb Vasc Biol. 2023; 44(2):366-390.

PMID: 38126170 PMC: 10872470. DOI: 10.1161/ATVBAHA.123.320279.


HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA.

Godfrey J, Hejazi D, Du X, Wei C, Rao E, Gomez C Int J Mol Sci. 2022; 23(17).

PMID: 36076950 PMC: 9455161. DOI: 10.3390/ijms23179549.


HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.

Hart V, Gautrey H, Kirby J, Tyson-Capper A Oncotarget. 2020; 11(46):4338-4357.

PMID: 33245725 PMC: 7679030. DOI: 10.18632/oncotarget.27789.


GPER-induced signaling is essential for the survival of breast cancer stem cells.

Chan Y, Lai A, Lin R, Wang Y, Wang Y, Chang W Int J Cancer. 2019; 146(6):1674-1685.

PMID: 31340060 PMC: 7003894. DOI: 10.1002/ijc.32588.


The Effect of Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population.

Gao Y, Tang X, Cao J, Rong R, Yu Z, Liu Y J Cancer. 2019; 10(2):378-387.

PMID: 30719131 PMC: 6360301. DOI: 10.7150/jca.27976.


References
1.
Lesko E, Majka M . The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci. 2007; 13:1271-80. DOI: 10.2741/2760. View

2.
Elias J, Gygi S . Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4(3):207-14. DOI: 10.1038/nmeth1019. View

3.
Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

4.
Molina M, Saez R, Ramsey E, Garcia-Barchino M, Rojo F, Evans A . NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002; 8(2):347-53. View

5.
Shin K, Lee M, Shin D, Lee S, Son K, Koh S . Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem. 2005; 280(50):41439-48. DOI: 10.1074/jbc.M507209200. View